Aberrations in RET/PTC-RAS-RAF-MAPK pathway are present in a high percentage of thyroid cancer, as well as angiogenesis switch alterations and involvement of other receptor tyrosine kinases, such as VEGFR or c-Met. This evidence concerns the gene MET and thyroid cancer.